Federated Hermes Inc. Buys 26,887 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Federated Hermes Inc. lifted its stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 25.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 130,688 shares of the biopharmaceutical company's stock after acquiring an additional 26,887 shares during the period. Federated Hermes Inc. owned 0.08% of TG Therapeutics worth $3,934,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the stock. Bleakley Financial Group LLC bought a new stake in TG Therapeutics during the 4th quarter valued at approximately $245,000. Castellan Group bought a new position in TG Therapeutics during the fourth quarter worth $8,539,000. Barclays PLC raised its stake in TG Therapeutics by 83.9% during the 3rd quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company's stock valued at $8,117,000 after purchasing an additional 158,323 shares during the last quarter. JPMorgan Chase & Co. grew its position in TG Therapeutics by 60.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 720,798 shares of the biopharmaceutical company's stock worth $16,859,000 after purchasing an additional 270,286 shares during the last quarter. Finally, Stratos Wealth Advisors LLC acquired a new position in shares of TG Therapeutics during the fourth quarter valued at about $241,000. Institutional investors own 58.58% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. HC Wainwright restated a "buy" rating and set a $55.00 price target on shares of TG Therapeutics in a research note on Tuesday, March 4th. StockNews.com upgraded TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $40.67.

TG Therapeutics Price Performance

Shares of TGTX traded up $0.11 during trading hours on Friday, hitting $38.32. The stock had a trading volume of 1,074,546 shares, compared to its average volume of 3,108,359. TG Therapeutics, Inc. has a 52 week low of $12.93 and a 52 week high of $43.32. The stock has a market capitalization of $6.02 billion, a price-to-earnings ratio of -383.16 and a beta of 2.14. The company's fifty day moving average is $36.20 and its two-hundred day moving average is $31.74. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.08 by $0.07. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The business had revenue of $108.19 million for the quarter, compared to the consensus estimate of $100.67 million. On average, analysts anticipate that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.